Clinical Trial Update: Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating adjuvant low-dose ketamine for pediatric sickle cell vaso-occlusive crisis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease
• Vaso-occlusive Crisis

Drugs mentioned

• Ketamine (ketamine)

Snippet

Sponsor: UCSF Benioff Children's Hospital Oakland | Conditions: Sickle Cell Disease, Vaso-Occlusive Crisis | Phase 2 | Status: COMPLETED | Results posted: 2021-04-20